Find Academic Supervisors

• Pharmaceutical Sciences
• Pharmacogenomics
• Transporter Biology
• +6 more

Kathy Giacomini is a Professor and Dean of the University of California San Francisco (UCSF) School of Pharmacy. She holds joint appointments in the Department of Cellular and Molecular Pharmacology (School of Medicine) and the Department of Pharmaceutical Chemistry . Her leadership focuses on advancing the School’s mission in research, education, and patient care, particularly in precision medicine and pharmacogenomics. Dr. Giacomini’s research centers on membrane transporter biology , including SLC22 family members like OCT1 and OCT3. Her work explores how genetic variation in transporters affects drug disposition and response, especially in anti-diabetic medications such as metformin and sulfonylureas. She co-leads the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (CERSI) , the first FDA-funded CERSI on the U.S. West Coast. Her recent publications highlight advances in transporter-mediated drug interactions, pharmacogenetic testing, and the role of excipients in drug absorption. Key research areas include metformin pharmacogenetics , transporter structural determinants , and precision medicine applications for ethnically diverse populations. Scientific Awards include election to the American Academy of Arts and Sciences (2024), Reynold Spector Award (2023), Volwiler Research Achievement Award (2018), and National Academy of Medicine membership (2006). She advocates for Diversity, Equity, and Inclusion , establishing the CERSI Diversity Scholars Program and promoting underrepresented minorities in pharmacogenomics and pharmaceutical sciences. Dr. Giacomini’s laboratory collaborates extensively with institutions like Stanford University and the Quantitative Biosciences Institute, advancing understanding of transporter proteins as therapeutic targets and determinants of drug safety.

• Medicinal Chemistry
• Antiparasitic Drug Discovery
• Organic Synthesis
• +7 more

Nicolas Primas is a Lecturer at the Faculty of Pharmacy, Aix-Marseille University, where he contributes to the Radical Pharmacochemistry (PCR) Team. His academic role encompasses teaching Chemical Design of Medicines, Pharmacochemistry, Green Chemistry, and Public Healthcare – Hydrology courses across DFGSP2, DFGSP3, and DFASP1 pharmacy programs, reflecting his dual expertise in medicinal chemistry and pharmaceutical technology. His research focuses on developing antiparasitic agents against neglected tropical diseases through heterocyclic molecule synthesis, particularly targeting malaria, leishmaniasis, and trypanosomiasis. Utilizing a Hit-to-Lead approach, he investigates structure-activity relationships, physicochemical properties, and pharmacokinetic parameters to identify molecular mechanisms of action and overcome resistance. Recent work emphasizes in vitro and in vivo validation using infected animal models, with strong translational focus on drug stability and formulation. Analysis of his 2022–2024 publications reveals dominant themes: antiplasmodial quinazoline/imidazopyridine derivatives targeting Plasmodium kinases (e.g., PfPYK-1), optimization of microsomal stability/intestinal permeability for thienopyrimidones, and pediatric formulation stability studies. His work bridges medicinal chemistry and pharmaceutical technology, addressing artemisinin resistance and low-dose compounding challenges. As part of the Radical Pharmacochemistry Team, Primas collaborates on Axis 2 projects (Bioactive Molecule Design) spanning organic synthesis, biological application development, and in vitro / in vivo validation. His laboratory integrates synthetic chemistry with pharmacological testing to advance anti-infective candidates toward preclinical development.

Monica DinescuView profile

Researcher

• Nanomaterials
• Photodegradation
• Pharmaceutical Analysis
• +5 more

Monica Dinescu serves as an Assistant Researcher at the National Institute of Materials Physics in Magurele, Romania, where she has been conducting research since 2013. She is simultaneously pursuing her PhD at University POLITEHNICA of Bucharest in the Faculty of Applied Chemistry and Materials Science. Her research focuses on the photodegradation mechanisms of pharmaceutical compounds using advanced spectroscopic techniques including UV-vis, FTIR absorption, Raman, and Photoluminescence. Her educational background includes a Master's degree in Micro and Nano-materials from University POLITEHNICA of Bucharest (2013-2015) and a Graduate degree in Chemical Engineering from the same institution (2009-2013), with specialization in Science and Engineering of Oxide Materials and Nano-materials. Dinescu's research interests center on the interaction between nanomaterials and pharmaceutical compounds, with particular emphasis on photodegradation processes. She investigates how materials like graphene oxide, carbon nanotubes, and TiO2 nanoparticles affect the stability of drugs including acetaminophen, nifedipine, ampicillin, and melatonin. Her work combines materials synthesis with advanced spectroscopic characterization to develop new analytical methods for pharmaceutical quality control. Analysis of her publication record reveals a strong focus on applying photoluminescence as a complementary tool to traditional UV-VIS spectroscopy for monitoring drug photodegradation. Her research demonstrates how different nanomaterials can either enhance or inhibit photodegradation processes, with implications for pharmaceutical formulation and storage. Dinescu has contributed to two patents related to pharmaceutical formulations and sensor development, demonstrating the practical applications of her research. Her work on azathioprine polymorphs and graphene-based sensors for epidermal growth factor receptor detection shows translational potential for drug development and medical diagnostics. She has collaborated extensively with Mihaela Baibarac and other researchers at the National Institute of Materials Physics, contributing to numerous publications that bridge materials science and pharmaceutical chemistry. Her expertise in spectroscopic characterization of drug-nanomaterial interactions positions her at the forefront of pharmaceutical nanotechnology research.

• Pharmaceutical Sciences
• Supramolecular Chemistry
• Thermodynamics
• +3 more

Jens Christian Sidney Schönbeck serves as a Teaching Associate Professor in the Department of Pharmacy at the Faculty of Health and Medical Sciences, University of Copenhagen. His academic profile integrates pharmaceutical education with advanced research in molecular interactions for drug delivery systems. Research interests focus on: Supramolecular host-guest chemistry of cyclodextrins and pillararenes Thermodynamic characterization of complexation processes Development of analytical methodologies for polydisperse pharmaceutical systems Solvent effects in molecular recognition Formulation science for improved drug stability His publication trajectory (2014-2025) demonstrates sustained expertise in pharmaceutical physical chemistry, with recent work addressing practical challenges like buffer selection for cyclodextrin formulations and innovative ITC applications for heterogeneous systems. This progression reflects both fundamental investigations into molecular interactions and applied solutions for pharmaceutical development.

Huiling MuView profile

Associate Professor

• Drug Delivery
• Lipid Biochemistry
• Nanoparticles
• +5 more

Huiling Mu is an Associate Professor at the Department of Pharmacy, University of Copenhagen, Denmark. She has held this position since 2009, following previous academic roles as Associate Professor at the Technical University of Denmark (2001-2009) and Assistant Professor in Biochemistry and Nutrition (1996-2000). Her research focuses on lipid biochemistry and pharmaceutical applications, particularly the relationship between lipid structures and their impact on drug/nutrient delivery systems. Research Interests: Dr. Mu specializes in molecular interactions of excipients, development of topical drug delivery systems, and characterization of lipid-based nanocarriers. Her work integrates: Formulation strategies for nanoparticles and microparticles In vitro and in vivo evaluation methodologies Advanced analytical techniques for system characterization Design of pH-responsive and hybrid delivery systems Her publications consistently explore innovations in lipid nanotechnology, buccal/sublingual delivery, and functional lipid design. With over 153 research outputs including 137 journal articles and 9 reviews, her scholarly work demonstrates sustained focus on: Nanocarrier optimization (cubosomes, hexosomes, SLNs) Novel delivery systems for peptides and poorly soluble drugs Biorelevant evaluation methodologies Plant-derived therapeutic applications Professional Activities: Dr. Mu serves as referee for >20 international journals including Nature Communications and Biomaterials , and evaluates grant applications for funding bodies in Israel, Netherlands, China, and Ireland. She teaches courses in Kemiske principper, Pharmaceutics and Drug Development, and Bachelor projects.

Anthony CurtisView profile

Senior Lecturer

• Nanopharmaceutics
• Drug Discovery and Delivery
• Synthetic Chemistry
• +3 more

Dr Anthony Curtis is a Senior Lecturer in Organic and Medicinal Chemistry at the School of Pharmacy and Bioengineering, Keele University. With a career spanning over 25 years at Keele, he has played a pivotal role in developing the MPharm program and advancing nanopharmaceutical research. Current focus on nanopharmaceutics and supramolecular delivery systems Collaborates with Dr Alan Richardson (Keele), Dr Jóhannes Reynisson (Keele), and Dr Clare Hoskins (University of Strathclyde) External Examiner for MPharm at Robert Gordon University His research addresses critical challenges in drug delivery through nanotechnology-enabled solutions , particularly for hydrophobic anticancer drugs. He has pioneered the use of calix[n]arenes and calix[4]resorcinarenes as solubilizing agents for creating responsive nano-carriers that release drugs under specific stimuli like pH changes. Recent publications demonstrate his work's impact across multiple subfields: Pancreatic cancer nanotherapy Thermoresponsive drug carriers Hybrid nanoparticle design Prodrug chemistry Controlled release mechanisms Anti-microbial resistance solutions Awarded: Keele University Excellence in Learning and Teaching Award (2008) Institute of Science and Technology in Medicine Research Fellowship (2015-2016) Professional memberships include: Royal Society of Chemistry (Fellow and Chartered Chemist), American Chemical Society, Academy of Pharmaceutical Sciences, and UK/Ireland Controlled Release Society.

Sarah HudsonView profile

Professor

• Pharmaceutical Sciences
• Materials Science
• Drug Delivery Systems
• +8 more

Sarah Hudson is a Professor at the University of Limerick's Department of Chemical Sciences and a Principal Investigator at the Bernal Institute and SSPC (Science Foundation Ireland Research Centre for Pharmaceuticals). She holds a PhD from the University of Limerick (2006) and conducted postdoctoral research at MIT under Prof. Robert Langer. Her expertise spans pharmaceutical formulation science, with a focus on improving drug solubility, stability, and bioavailability through advanced material science approaches. Education: PhD, University of Limerick (2006) Masters by Research, Trinity College Dublin (2000) BA (Mod), Trinity College Dublin (1999) Research Interests: Manipulation of physicochemical properties of active pharmaceutical ingredients (APIs) Thermodynamics of aggregation, crystallization, and precipitation in biorelevant environments Development of formulations to control solution/solid-state behavior of drugs Nanoparticle and hydrogel-based drug delivery systems Articles Trends: Recent work emphasizes drug delivery systems (e.g., hydrogels, SLNs), crystallization control in pharmaceuticals, and antimicrobial peptide formulations. Studies address challenges in bioavailability enhancement and overcoming antimicrobial resistance. Awards: Academic Partner in Enterprise Ireland Commercialisation Grant (2013) Best Post-graduate Web of Science Journal Publication (2007) Disruptive Technologies Award (2019) Advising & Grants: Supervised over 20 PhD/MSc students and postdocs, funded by SFI, Marie Curie ITN, and industry partners (e.g., Janssen, Allergen). Active in SSPC and EU-funded initiatives. Labs/Teams: Leads the Hudson Group within the Bernal Institute, collaborating on projects in drug formulation, nanotechnology, and sustainable pharmaceutical development.

Pengli BuView profile

Assistant Professor

• Reproductive Pharmacology
• Toxicology
• Herbal Medicine
• +3 more

Pengli Bu, Ph.D. serves as an Assistant Professor in the Department of Pharmaceutical Sciences within the College of Pharmacy and Health Sciences at St. John's University, having joined in Fall 2022. Previously, she held an Assistant Professor position at Rosalind Franklin University of Medicine and Science (2019-2022). Her educational background includes: Ph.D. in Toxicology from University of Kansas Medical Center M.S. in Biochemistry and Molecular Biology from Peking Union Medical College, China B.S. in Biochemistry and Molecular Biology from Shandong University, China Dr. Bu's research focuses on reproductive pharmacology and toxicology, with emphasis on harnessing herbal medicine for Leydig cell protection, investigating transporters in metabolic diseases, and conducting safety assessments of biopharmaceuticals. Her work bridges molecular mechanisms with therapeutic applications, particularly in endocrine and reproductive systems. Analysis of her recent publications reveals strong trends in reproductive toxicology, molecular mechanisms of drug action, and transporter biology. Her work frequently employs advanced cellular models including Caco-2 and yeast systems, with significant contributions to understanding cytokine regulation in endometrial biology, perfluorochemical impacts on gene expression, and herbal compound mechanisms. Dr. Bu maintains active research in pharmaceutical sciences with consistent publication output in high-impact journals including Journal of Biological Chemistry, Toxicology, and Journal of Pharmacology and Experimental Therapeutics.

Tai-De LiView profile

Associate Professor

• Biophysics
• Nanoscience
• Surface Science
• +3 more

Dr. Tai-De Li serves as Research Associate Professor at the Advanced Science Research Center (ASRC) of the City University of New York (CUNY), concurrently managing the Surface Science Facility since 2015. His academic journey includes a PhD in Physics from Georgia Institute of Technology, postdoctoral research at UC Berkeley and Lawrence Berkeley National Lab, and undergraduate/master's training at National Taiwan University. His educational credentials: National Taiwan University: Undergraduate and Master's degrees Georgia Institute of Technology: PhD in Physics Dr. Li's research centers on mechanical-biochemical interfaces in biological systems (cytoskeleton actin networks, thylakoid membranes) and surface science applications for 2D semiconductor thin films. His work bridges fundamental biophysics with nanoelectronics development, characterized by extensive cross-disciplinary collaborations across physics, chemistry, biology, and engineering disciplines. Current investigations focus on nanoscale material properties essential for next-generation electronic devices. Analysis of his 2022-2025 publications reveals dominant themes in energy materials (perovskite solar cells, lithium-sulfur batteries, fuel cells) and biomimetic systems (peptide-based nanomaterials, 2D interfaces). His output demonstrates consistent high-impact contributions to nanoscience, with particular emphasis on interfacial phenomena governing device performance in energy conversion and storage applications. As Surface Science Facility Manager, Dr. Li oversees critical instrumentation for surface characterization, supporting ASRC's research ecosystem. His leadership enables advanced studies of nanoscale mechanical, electrical, and biochemical properties across multiple research groups. Current projects involve collaborations on peptide nanofibers, semiconductor interfaces, and energy materials requiring precise surface analysis capabilities.

Celine Valeria LiewView profile

Associate Professor

• Granulation and Pelletization
• Preformulation and Material Characterization
• Multiparticulate Dosage Forms
• +3 more

Celine Valeria Liew is an Associate Professor at the School of Pharmacy, Monash University Malaysia. She holds a BSc (Pharm) (Hons) and PhD from the National University of Singapore (NUS). Her career includes roles as a Pharmacist in Singapore's Ministry of Health, a Research Fellow at NUS, and faculty at NUS until 2021. She also worked as a Senior Scientist at Niro Inc., USA. Her research focuses on granulation, pelletization, preformulation, and pharmaceutical manufacturing, with contributions to UN Sustainable Development Goals related to education and health. Education: Bachelor of Science in Pharmacy, National University of Singapore (1990) Bachelor of Science in Pharmacy (Hons), National University of Singapore (1991) PhD in Pharmaceutics, National University of Singapore (1996) Research Interests: Granulation and pelletization techniques Preformulation and material characterization Development of multiparticulate dosage forms Pharmaceutical manufacturing of powders, tablets, and capsules Excipient functionality and moisture management in drug formulations Recent Projects: Mechanistic understanding of rapid disintegrant action in orally disintegrating tablets (2022–2025) Awards: Liew Weng Chee Scholarship (2005) Professional Activities: Invited speaker at International Conference in Pharmaceutics and Cosmetics (2024) Workshop leader on granulation and pelletization techniques (2023–2024)

Farzaneh HajirasoulihaView profile

Research Fellow

• Interfacial Sciences
• Nanoparticle Toxicology
• Surfactant Chemistry
• +4 more

Farzaneh Hajirasouliha is a Research Fellow at the University of Hertfordshire's Centre for Research into Topical Drug Delivery and Toxicology, part of the School of Life and Medical Sciences. She holds a PhD in Mechanical Engineering from Northumbria University (2019–2022), an MSc in Chemical Engineering-Pharmaceutical Engineering from the University of Tehran (2011–2014), and a BSc in Chemical Engineering-Food Industry from Amirkabir University of Technology (2007–2011). Her research focuses on interfacial sciences, nanoparticle behavior at air-liquid interfaces, surfactant systems, and sustainable pharmaceutical formulations. Key areas include nanotoxicology, colloidal stability, and environmental impacts of nanomaterials. She has published extensively on titanium dioxide nanoparticles' effects on lung surfactants and developed novel methods for material characterization (e.g., UV spectroscopy for chitosan modification). Current projects include an RSC-funded Travel Grant (2024–2025) supporting researcher development. Her work bridges fundamental interfacial science with practical applications in drug delivery and environmental health. Research interests span: biofilm dynamics on structured substrates, viscoelastic material design, and eco-friendly pharmaceutical formulations. Collaborations include studies on anti-biofilm methods and wetting phenomena in porous media.

• Protein therapeutics formulation
• Biopharmaceutical delivery systems
• Protein-material interactions
• +3 more

Reza Nejadnik is an Associate Professor in the Department of Pharmaceutical Sciences and Experimental Therapeutics at the University of Iowa College of Pharmacy. His research focuses on protein pharmaceuticals, formulation optimization, and biophysical characterization of therapeutic proteins. He holds a PhD in Materials Science and Engineering from the University of Groningen, Netherlands, with postdoctoral experience at institutions including The University of Texas, Northwestern University, and Radboud University Nijmegen. Prior to academia, he led formulation development at Sanofi's Global Biologic Drug Product team in Frankfurt, Germany. His work addresses challenges in protein aggregation, surfactant removal, and stability during manufacturing and delivery processes. Education: PhD: Materials Science and Engineering, University of Groningen (2009) MSc: Biomedical Engineering (Biomaterials), Amirkabir University of Technology BSc: Materials Science and Engineering, Isfahan University of Technology Research Interests: Formulation and delivery of monoclonal antibodies and novel biologics Protein-surface interactions and adsorption mechanisms Stability of protein therapeutics under handling/administration conditions Development of closed-system drug delivery devices Recent Research Trends: Recent studies emphasize formulation challenges in surfactant removal, antibody stability under compounding conditions, and aggregate formation during infusion. His work bridges fundamental biophysical insights with translational drug product development. Labs/Teams: Directs the Nejadnik Laboratory, focusing on advancing protein pharmaceutical formulation and delivery technologies. Collaborates widely with industry partners and academic researchers in Europe and North America.

• Pharmaceutical Solids
• Material Science
• Polymorphism
• +7 more

Raj Suryanarayanan serves as Professor, William & Mildred Peters Endowed Chair, and Department Head of the Department of Pharmaceutics at the University of Minnesota. His research program focuses on the material science of pharmaceutical solids, with particular emphasis on physical characterization of polymorphic forms, crystallinity, and water interactions in drug products. Education: PhD in Pharmaceutics, University of British Columbia MPharm in Pharmaceutics, Indian Institute of Technology, Varanasi BPharm in Pharmaceutics, Indian Institute of Technology, Varanasi Research Focus: Dr. Suryanarayanan's laboratory investigates phase transitions during pharmaceutical processing using advanced techniques including X-ray powder diffractometry, thermoanalytical methods, spectroscopy, and microscopy. Key research areas include in-situ monitoring of freeze-drying cycles for protein pharmaceuticals, quantification of rapid reaction phases (40 msec resolution), microdiffractometry for tablet surface mapping, and development of novel excipients for freeze-dried formulations. His work bridges fundamental material science with practical formulation challenges to ensure reproducible solid dosage form performance. Publication Trends: Recent publications (2023-2025) reveal a dominant focus on monoclonal antibody stability in freeze-dried systems, excipient functionality (particularly mannitol and sucrose), and advanced characterization of frozen solutions. The research demonstrates sophisticated integration of solid-state NMR, X-ray diffraction, and thermal analysis to resolve phase transitions and molecular mobility issues. A clear trajectory emerges toward solving industry-relevant problems in biologics formulation, with increasing emphasis on predictive stability models and continuous manufacturing implications. Scientific Recognition: Honored with a dedicated issue of the Journal of Pharmaceutical Sciences (January 2023) Research Leadership: As Department Head and Endowed Chair, Dr. Suryanarayanan directs the Sury Research Group which has secured significant funding including GOALI/Collaborative Research awards. His laboratory maintains specialized instrumentation for real-time monitoring of pharmaceutical processing, particularly custom-built systems for freeze-drying cycle optimization. The group maintains strong industry collaborations focused on solving critical formulation challenges in protein therapeutics and amorphous solid dispersions. Facilities: The Sury Lab operates advanced characterization equipment including synchrotron X-ray diffractometers, solid-state NMR, and custom microdiffractometry systems specifically engineered for mapping tablet heterogeneity and monitoring rapid phase transitions during processing.

Jan Henrik FinkeView profile

Lecturer

• Pharmaceutical Technology
• Particle Engineering
• Drug Delivery Systems
• +6 more

Jan Henrik Finke is a Lecturer and Head of the Division for Pharma and Bio Particle Technology at the Institute for Particle Technology (iPAT) within the Faculty of Mechanical Engineering at Braunschweig University of Technology. He also serves as a Senior Scientist at the Fraunhoig Institute for Surface Engineering and Thin Films since 2020, and previously held a part-time Substitute Professorship in Pharmaceutical Technology at Friedrich-Schiller-University Jena during the 2021/22 academic year. Dr. Finke completed his doctorate in 2014 with research focused on 'Manufacturing colloidal drug delivery systems in customized microsystems: Characterization of process efficiency and interactions.' He studied Pharmacy at the University of Münster from 2002-2006 and has since built an extensive career in pharmaceutical technology and particle engineering. His research interests span pharmaceutical technology, particle engineering, drug delivery systems, microsystems engineering, and 3D printing of pharmaceuticals. Dr. Finke's work focuses on developing innovative approaches for drug formulation, particularly for poorly water-soluble compounds, and advancing manufacturing processes for pharmaceutical products including probiotic formulations and personalized medicine. Analysis of his recent publications (2023-2025) reveals a strong focus on pharmaceutical manufacturing challenges, particularly tablet production with living microorganisms, advanced drug delivery systems, and the application of computational modeling to pharmaceutical processes. His work bridges fundamental particle technology with practical pharmaceutical applications, with increasing emphasis on personalized medicine approaches through 3D printing technologies. Dr. Finke has made significant contributions to understanding the survival of microorganisms during pharmaceutical processing, the development of novel drug delivery systems, and the optimization of manufacturing processes for complex pharmaceutical formulations. His research has practical implications for improving drug bioavailability and developing personalized medication approaches. As Head of the Pharma and Bio Particle Technology division, Dr. Finke leads research efforts focused on particle-based pharmaceutical technologies, including nanoparticle formulations, solid lipid nanoparticles, and advanced manufacturing techniques for drug delivery systems. His work connects engineering principles with pharmaceutical sciences to address challenges in modern drug development and manufacturing.

Oliver GermershausView profile

Professor

• Pharmaceutical Technology
• Biotechnology
• Drug Delivery Systems
• +7 more

Oliver Germershaus is Professor for Pharmaceutical Technology of Macromolecular Drugs at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) , where he serves as Head of Institute for Pharma Technology and Biotechnology . He holds a School of Life Sciences affiliation and licenses as a pharmacist in Germany. Academic background includes: PhD in Pharmaceutical Sciences (University of Marburg, 2007) MSc in Pharmacy (University of Halle-Wittenberg, 2003) University of Marburg education (2002) Research focuses on drug delivery systems for large molecules including peptides, proteins, and nucleic acids. His work spans biopharmaceutical formulation development , excipient interaction analysis , and packaging compatibility studies . Key methodologies include white light interferometry for medical device characterization, self-assembling peptide hydrogels for localized drug delivery, and MMP-responsive systems for bioactive material design. Recent publications demonstrate expertise in: Standard particle fabrication via micro 3D printing (2024) PS20 surfactant degradation patterns in mAb formulations (2024) Alternative surfactant selection for biopharmaceuticals (2023) Silk fibroin modification for implant applications (2018) Medical device lubrication analysis (2018) Matrix metalloprotease responsive systems (2018) Professional memberships include: Swiss Academy of Pharmaceutical Sciences (SAPhW) Controlled Release Society (CRS) Germany Chapter Swiss Society of Industrial Pharmacists (GSIA) Parenteral Drug Association (PDA) American Chemical Society (ACS) Academic leadership roles: Co-Organizer PharmaLunch Basel Editorial Board, Asian Journal of Pharmaceutical Sciences Reviewer for German Research Foundation and 10+ journals